reports
Rosetta Genomics Fortifies Patent Protection for its Unique RosettaGX ...
PHILADELPHIA & REHOVOT, Israel--(BUSINESS WIRE)-- Rosetta Genomics Ltd. (NASDAQ:ROSG), a genomic diagnostics company that improves treatment decisions by providing timely and accurate diagnostic information to physicians, today announces that the United States Patent and Trademark Office (USPTO) has granted a patent allowance for patent application No. 15/237,364, relating to “miRNA Expression Signature in the Classification of Thyroid Tumors.” The allowed patent claims a method of classifying a thyroid lesion sample obtained by fine needle ...
Rosetta Genomics Announces 1-for-12 Reverse Stock Split
PHILADELPHIA & REHOVOT, Israel--(BUSINESS WIRE)-- Rosetta Genomics Ltd. (NASDAQ: ROSG), a genomic diagnostics company that improves treatment decisions by providing timely and accurate diagnostic information to physicians, announces the effectiveness of a 1-for-12 reverse stock split of its share capital. The reverse stock split, which was previously approved by the Company’s Board of Directors, was approved by its shareholders at an Extraordinary General Meeting of Shareholders of the Company held earlier today. The reverse ...
Rosetta Genomics Closes Second Tranche of Previously Announced Private...
PHILADELPHIA & REHOVOT, Israel--(BUSINESS WIRE)-- Rosetta Genomics Ltd. (NASDAQ:ROSG), a genomic diagnostics company that improves treatment decisions by providing timely and accurate diagnostic information to physicians, announces the closing of the second tranche of the private placement of convertible debentures previously announced on November 23, 2016. The closing of this second tranche involved the sale of newly registered convertible debentures (convertible into 2,585,000 ordinary shares) for gross proceeds of $1,292,500. The Company ...
Rosetta Genomics Reports Preliminary RosettaGX Revealâ„¢ Financial Res...
PHILADELPHIA & REHOVOT, Israel--(BUSINESS WIRE)-- Rosetta Genomics Ltd. (NASDAQ:ROSG), a genomic diagnostics company that improves treatment decisions by providing timely and accurate diagnostic information to physicians, announces preliminary financial results and unit growth for its RosettaGX Reveal™ (Reveal) assay for the classification of indeterminate thyroid nodules, for the three months and year ended December 31, 2016. Preliminary Reveal revenue for the fourth quarter of 2016 was approximately $390,000, representing g...
Rosetta Genomics Announces Key U.S. Patent Allowances for Two RosettaG...
PHILADELPHIA & REHOVOT, Israel--(BUSINESS WIRE)-- Rosetta Genomics Ltd. (NASDAQ:ROSG), a genomic diagnostics company that improves treatment decisions by providing timely and accurate diagnostic information to physicians, announces that the United States Patents and Trademark Office (USPTO) has granted two patent allowances for patent applications US 14/756,185 (‘185) and US 14/999,879 (‘879), both divisional patents of the parent application titled “microRNAs and uses thereof.” Application ‘185 claims hsa-miR-146-5p, its com...
Ford Equity International Rating and Forecast Report
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind...
Rosetta Genomics Announces Pricing of $5 Million Concurrent Registered...
PHILADELPHIA & REHOVOT, Israel--(BUSINESS WIRE)-- Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostic testing services, today announced it has entered into definitive agreements with one prominent institutional healthcare investor to purchase an aggregate of 1,095,000 ordinary shares at a purchase price per share of $0.50 and registered convertible debentures (convertible into 6,320,000 ordinary shares) in a registered direct offering, as well as unregistered convertible ...
Rosetta Genomics Enters Research Collaboration using microRNA Biomarke...
PHILADELPHIA & REHOVOT, Israel--(BUSINESS WIRE)-- Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, announces that the Company has entered into a research agreement with Sheba Medical Center at Tel HaShomer, Israel, to develop a microRNA-based signature to predict response to Nivolumab, an immunotherapy drug marketed as Opdivo®, which is approved for the treatment of lung cancer patients. The prospective study, “Circulating microRNA Biomarkers for Lung Cancer ...
Clinical Validation Study for RosettaGX Reveal Published in the Journa...
PHILADELPHIA & REHOVOT, Israel--(BUSINESS WIRE)-- Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, announces that a clinical validation study in support of RosettaGX Reveal™ (Reveal), the Company’s first-of-its-kind microRNA classifier for indeterminate thyroid nodules, has been published in the Journal of Clinical Pathology. The article, entitled “Multicenter Validation of a MicroRNA-based Assay for Diagnosing Indeterminate Thyroid Nodules Utilizing Fine Needle A...
RosettaGX Revealâ„¢ Analytical Validation Study Featured on the Cover ...
PHILADELPHIA & REHOVOT, Israel--(BUSINESS WIRE)-- Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, announces that an article highlighting the analytical validation data from a study of the Company’s novel, microRNA-based assay for the classification of indeterminate thyroid nodules is featured on the cover of the October issue of the peer-reviewed journal, Cancer Cytopathology. These data were previously published in the journal’s online edition in an ar...
Rosetta Genomics Appoints Mark R. Willig as Chief Commercial Officer
PHILADELPHIA & REHOVOT, Israel--(BUSINESS WIRE)-- Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, announces the appointment of Mark R. Willig as Chief Commercial Officer. In this newly created position, Mr. Willig will be responsible for sales, marketing and market access for Rosetta Genomics’ entire portfolio of high-value diagnostic assays. He will report to Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics. Throughout his ca...
Rosetta Genomics Fortifies Intellectual Property Portfolio with Two Ne...
PHILADELPHIA & REHOVOT, Israel--(BUSINESS WIRE)-- Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announced that the Company has added two new patent allowances to its intellectual property portfolio for its microRNA platform technology. With these new allowances, Rosetta Genomics has 64 granted or allowed patents and 33 patents pending. Rosetta Genomics has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for U.S. ...
Rosetta Genomics Enters Distribution Agreement for RosettaGX Revealâ„¢...
PHILADELPHIA & REHOVOT, Israel--(BUSINESS WIRE)-- Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announced that the Company has entered into an exclusive distribution agreement with Rhenium Ltd. for the sales and marketing of RosettaGX Reveal™ (Reveal), the Company’s first-of-its-kind microRNA classifier for indeterminate thyroid nodules, in Israel. Under the terms of the agreement, Rhenium’s exclusivity is contingent on Rhenium meeting certain volume commitment...
Rosetta Genomics Reports 2016 Second Quarter Financial Results
PHILADELPHIA & REHOVOT, Israel--(BUSINESS WIRE)-- Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, reports financial results for the three and six months ended June 30, 2016. Recent developments include: Gross billings for RosettaGX Reveal™ (“Reveal”), the Company’s first-of-its-kind microRNA classifier for indeterminate thyroid nodules, are tracking to be approximately $1.5 million for the first nine months of 2016; ...
Rosetta Genomics to Host 2016 Second Quarter Financial Results and Bus...
PHILADELPHIA & REHOVOT, Israel--(BUSINESS WIRE)-- Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announced that the Company will file its financial results for the three and six months ended June 30, 2016 on Form 6K with the U.S. Securities and Exchange Commission (“SEC”) after the closing of the U.S. financial markets on September 26, 2016. The Form 6K will include unaudited consolidated financial statements, as well as additional information regarding the ...
Rosetta Genomics to Present at Upcoming September Conferences
PHILADELPHIA & REHOVOT, Israel--(BUSINESS WIRE)-- Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announces that Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics, will be delivering a corporate overview at the 2016 Aegis Growth Conference taking place September 20-22, 2016 in Las Vegas and at the Ladenburg Thalmann 2016 Healthcare Conference taking place on September 27, 2016 in New York City. 2016 Aegis Growth Conferen...
Data Validating the Utility of RosettaGX Revealâ„¢ with Liquid-based C...
PHILADELPHIA & REHOVOT, Israel--(BUSINESS WIRE)-- Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announces the results from an analytical validation study confirming that the Company’s first-of-its-kind microRNA classifier for indeterminate thyroid nodules, RosettaGX Reveal™ (“Reveal”), can now be used with liquid-based cytology samples (ThinPrep®). The data will be presented in a poster at the upcoming 86th Annual Meeting of the American Thyroid Associati...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.